By Joseph Keenan
Publication Date: 2026-03-04 13:40:00
Nvidia, the computer chip giant, continues its deep dive into expanding artificial intelligence technology in the medtech and cancer research arenas, this time with diagnostics maker Droplet Biosciences.
Droplet, which focuses on lymph-based liquid biopsy testing, has leveraged Nvidia’s AI infrastructure Parabricks, a GPU-accelerated software that dramatically speeds genomic data analysis for DNA sequencing, the company said in a March 3 press release.
The diagnostics company cited a new case study that indicated a significant reduction in key analysis steps that went from days to hours using Parabricks.
Variant calling, which identifies differences between a person’s DNA sequence and a known reference genome to detect genetic variations responsible for diseases, was reduced from taking up to 36 hours to less than three hours. Sequence alignment saw a reduction from about 10 hours to just under one hour with overall analysis timelines shrunk from 10 days to two days.
“By leveraging NVIDIA Parabricks’ acceleration, we’ve been able to compress some of our most computationally intensive steps from more than a day down to just a few hours,” Wendy Winckler, Ph.D., Droplet’s chief science officer, said in a statement. “That speed matters. It means clinicians can get critical information sooner, make decisions at a more impactful moment, and ultimately deliver better, more personalized care for patients.”
Nvidia has…
